Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ONCONOVA THERAPEUTICS, INC.

(ONTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ONCONOVA THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)

05/14/2021 | 07:34am EDT

Item 3.01. Notice of Delisting or Failure to Satisfy a Continuing Listing Rule or Standard; Transfer of Listing.

On May 11, 2020, Onconova Therapeutics, Inc. (the "Company") received a letter from The Nasdaq Capital Market ("Nasdaq") indicating that the Company has failed to comply with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Nasdaq Listing Rule 5550(a) (2) requires that companies listed on Nasdaq maintain a minimum closing bid price of at least $1.00 per share.

Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a 180 calendar day grace period, or until November 8, 2021, to regain compliance by meeting the continued listing standard. The continued listing standard will be met if the Company's common stock has a minimum closing bid price of at least $1.00 per share for a minimum of ten consecutive business days during the 180 calendar day grace period.

If the Company is not in compliance by November 8, 2021, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intention to cure the minimum bid price deficiency during the second compliance period, by effecting a reverse stock split, if necessary.

If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. At that time, the Company may appeal the Nasdaq Staff's determination to a Nasdaq Hearings Panel.

The Company intends to monitor the closing bid price of the Company's common stock and consider its available options to resolve the noncompliance with the minimum bid price requirement. There can be no assurance that the Company will be able to regain and sustain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.

© Edgar Online, source Glimpses

All news about ONCONOVA THERAPEUTICS, INC.
06/11ONCONOVA THERAPEUTICS  : Announces participation in a.g.p.'s upcoming virtual su..
AQ
06/10ONCONOVA THERAPEUTICS  : Announces Participation in A.G.P.'s Upcoming Virtual Su..
AQ
06/03ONCONOVA THERAPEUTICS  : Announces Upcoming Presentation at 2021 BIO Digital
AQ
06/01ONCONOVA THERAPEUTICS  : Announces the Appointment of Mark Gelder, M.D., as Chie..
AQ
05/28ONCONOVA THERAPEUTICS  : May 28, 2021 - Proxy Statements
PU
05/24ONCONOVA THERAPEUTICS  : Announces the initial dosing of the first patient in th..
AQ
05/21Wall Street Higher Pre-Bell; Housing, PMI Data on Tap
MT
05/21ONCONOVA THERAPEUTICS  : Initiates Phase 1 ON 123300 Cancer Trial; Shares Soar P..
MT
05/21ONCONOVA THERAPEUTICS  : Announces the Initial Dosing of the First Patient in th..
AQ
05/21ONCONOVA THERAPEUTICS  : Announces reverse stock split and decrease in authorize..
AQ
More news
Financials (USD)
Sales 2021 0,18 M - -
Net income 2021 -22,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,04x
Yield 2021 -
Capitalization 112 M 112 M -
Capi. / Sales 2021 630x
Capi. / Sales 2022 797x
Nbr of Employees 12
Free-Float 99,5%
Chart ONCONOVA THERAPEUTICS, INC.
Duration : Period :
Onconova Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCONOVA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 20,00 $
Last Close Price 7,07 $
Spread / Highest target 310%
Spread / Average Target 183%
Spread / Lowest Target 55,6%
EPS Revisions
Managers and Directors
NameTitle
Steven M. Fruchtman President, Chief Executive Officer & Director
Mark P. Guerin Chief Financial Officer
James J. Marino Chairman
Matthew Parris Vice President-Clinical Operations
Viren Mehta Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ONCONOVA THERAPEUTICS, INC.1.19%112
CSL LIMITED4.75%103 884
WUXI BIOLOGICS (CAYMAN) INC.21.40%67 880
BIOGEN INC.61.99%59 716
SAMSUNG BIOLOGICS CO.,LTD.2.30%50 040
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.30.69%48 336